Publications : Details
Acceptability of Microarray Patches for Delivery of HIV Pre-exposure Prophylaxis (PrEP) Among Women and Health Care Providers in South Africa
As part of PATH’s work in vaccine and pharmaceutical delivery technologies, this poster presents results from a user-acceptability study of two microarray patches (MAPs) in South Africa. The MAPs under assessment were designed for the self-administration of antiretrovirals, such as rilpilvirine, and may someday offer a discreet and effective form of PrEP protection for women at risk of HIV.
Corporate author(s): PATH
Publication date: May 2016
Available materials
English
1,554 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
See also:
- Emerging and epidemic diseases > Drug development > HIV and AIDS
- Health technologies > Vaccine delivery
- Reproductive health > Sexually transmitted infections
For more information…
Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA